Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST – The Manila Times
- Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST The Manila Times
- Phase 3 PEAK Trial: Bezuclastinib Plus Sunitinib Improves PFS in Advanced GIST After Imatinib Consultant360
- Cogent Biosciences (COGT) Receives FDA Acceptance for New Drug A GuruFocus
- Cogent Biosciences announces FDA acceptance of bezuclastinib NDA TipRanks
- Cancer drug combo halves disease progression risk in GIST trial Stock Titan
0
مشاهدة